Introduction
Patients and methods
Patients
Parameter | Patients (n = 119) | Lesion treatment failure (n = 34) | Lesion treatment success (n = 85) | p |
---|---|---|---|---|
Mean age at surgery | 13 years (5 months–47 years) | 10.5 years (5 months–40 years) | 14.1 years (3–47 years) | 0.03b |
Mean follow-up time | 4.8 years (1–30 years) | 5.7 years (1–16 years) | 4.5 years (1–30 years) | 0.1c |
Mean time to revision surgerya | 25.4 months (5–84 months) | 25.4 months (5–84 months) | – | – |
Sex (male/female) | 79 (66%)/40 (34%) | 18 (53%)/16 (47%) | 61 (72%)/24 (28%) | 0.1d |
Localization | ||||
Humerus | 68 (57%) | 23 (68%) | 45 (53%) | 0.2d |
Femur | 26 (22%) | 8 (24%) | 18 (21%) | 0.7d |
Tibia | 11 (9%) | 1 (3%) | 10 (12%) | 0.2d |
Calcaneus | 5 (4%) | 1 (3%) | 4 (5%) | 0.8d |
Fibula | 3 (3%) | 0 | 3 (4%) | 0.5d |
Radius | 2 (2%) | 1 (3%) | 1 (1%) | 0.9d |
Scapula | 1 (1%) | 0 | 1 (1%) | 0.7d |
Acetabulum | 1 (1%) | 0 | 1 (1%) | 0.6d |
Ischium | 1 (1%) | 0 | 1 (1%) | 0.5d |
Ilium | 1 (1%) | 0 | 1 (1%) | 0.6d |
Finding | ||||
Pathological fracture | 72 (61%) | 25 (74%) | 47 (55%) | 0.2d |
Pain | 28 (24%) | 5 (15%) | 23 (27%) | 0.4d |
Incidental | 12 (10%) | 1 (3%) | 11 (13%) | 0.3d |
N/A | 7 (6%) | 3 (9%) | 4 (5%) | 0.9d |
Primary surgical treatment | ||||
Open surgery and curettage | 119 (100%) | 34 (100%) | 85 (100%) | – |
Burring | 79 (66%) | 22 (65%) | 57 (67%) | 0.6d |
Phenolization | 40 (34%) | 14 (41%) | 26 (31%) | 0.2d |
Filling total | 112 (94%) | 32 (94%) | 80 (94%) | 0.7d |
Autogenous bone filling | 12 (10%) | 3 (9%) | 9 (11%) | 0.4d |
Allograft bone chips filling | 96 (81%) | 28 (82%) | 68 (80%) | 0.8d |
Strut graft bone filling | 7 (6%) | 3 (9%) | 4 (5%) | 0.4d |
Bone substitute material filling | 15 (13%) | 4 (12%) | 11 (13%) | 0.9d |
Plate osteosynthesis | 38 (32%) | 9 (26%) | 29 (34%) | 0.5d |
Decompression screw | 1 (1%) | 0 | 1 (1%) | 0.5d |
External fixator | 1 (1%) | 0 | 1 (1%) | 0.6d |
Surgical indications
Surgical technique
Follow-up examination
Modified Neer classification
Definition of lesion treatment failure
Statistical analysis
Results
Lesion treatment failure rate after open surgical UBC treatment
Parameter | Lesion treatment failure (n = 34) | Revision lesion treatment failure (n = 10) | p | |
---|---|---|---|---|
Recurrences/persistent cysts | 30/8 | – | – | |
Recurrences/persistent cysts without revision surgery | 4/0 | – | – | |
Open revision surgery | 23 (68%) | 4 | 0.03b | |
Percutaneous revision surgery | 11 (32%) | 6 | 0.03b | |
Number of 3rd revisions for treatment failures | 0 | – | – | |
Total number of revision surgeriesa | ||||
Patient with one revision surgery | 38 | – | – | |
Patients with two revision surgeries | 22 | – | – | |
Patients with three revision surgeries | 2 | – | – |
Complications and consecutive procedures
Parameters associated with lesion treatment failure
Parameter | Patients (n = 59) | Lesion treatment failure (n = 20) | Lesion treatment success (n = 39) | p |
---|---|---|---|---|
Lesion volume | 55.4 (0.7–234.4) cm3 | 54.9 (0.7–165) cm3 | 55.7 (1.6–234.4) cm3 | 0.96a |
Distance UBC to nearest growth plate | 34.4 (0–112) mm | 21 (0–80) mm | 44.5 (0–112) mm | 0.02a |
Cyst septation (yes/no) | 24 (41%)/35 (59%) | 12 (60%)/8 (40%) | 12 (31%)/27 (69%) | 0.03b |
Number of visible chambers | 1.6 (1–5) | 2 (1–5) | 1.4 (1–3) | 0.02a |
Modified Neer score 6 months | 1.6 (1–4) | – | – | – |
Modified Neer score 12 months | 1.9 (1–4) | – | – | – |
Modified Neer score 2 years | 1.5 (1–4) | – | – | – |
Modified Neer score at last follow-up | 1.9 (1–4) | – | – | – |